[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA95274C2 - Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления - Google Patents

Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления

Info

Publication number
UA95274C2
UA95274C2 UAA200810224A UAA200810224A UA95274C2 UA 95274 C2 UA95274 C2 UA 95274C2 UA A200810224 A UAA200810224 A UA A200810224A UA A200810224 A UAA200810224 A UA A200810224A UA 95274 C2 UA95274 C2 UA 95274C2
Authority
UA
Ukraine
Prior art keywords
irbesartan
manufacture
solid pharmaceutical
processes
pharmaceutical composition
Prior art date
Application number
UAA200810224A
Other languages
English (en)
Ukrainian (uk)
Inventor
Миха Врбинч
Рената Яксе
Франчи Бевеч
Силво Жупанчич
Original Assignee
Крка, Д.Д. Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крка, Д.Д. Ново Место filed Critical Крка, Д.Д. Ново Место
Publication of UA95274C2 publication Critical patent/UA95274C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к области фармацевтики и касается твердого фармацевтического препарата, содержащего в качестве активного ингредиента ирбесартана гидрохлорид и необязательно гидрохлоротиазид, а также содержит маннитол, низкозамещенную гидроксипропилцеллюлозу и по меньшей мере одно смазывающее вещество, выбранное из полиэтиленгликоля, талька и гидрогенизированного касторового масла. Кроме того, изобретение касается способов изготовления таких препаратов путем влажной грануляции (А) или прямой грануляции (Б).
UAA200810224A 2006-01-09 2007-01-05 Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления UA95274C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06000329A EP1806130B1 (en) 2006-01-09 2006-01-09 Solid pharmaceutical composition comprising irbesartan

Publications (1)

Publication Number Publication Date
UA95274C2 true UA95274C2 (ru) 2011-07-25

Family

ID=35744710

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810224A UA95274C2 (ru) 2006-01-09 2007-01-05 Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления

Country Status (15)

Country Link
US (1) US20110045097A1 (ru)
EP (2) EP1806130B1 (ru)
CN (1) CN101370484B (ru)
AT (1) ATE462414T1 (ru)
CA (1) CA2636663A1 (ru)
DE (1) DE602006013261D1 (ru)
EA (1) EA016579B1 (ru)
ES (1) ES2340701T3 (ru)
HR (1) HRP20100216T1 (ru)
NO (1) NO20083183L (ru)
PL (1) PL1806130T3 (ru)
PT (1) PT1806130E (ru)
SI (1) SI1806130T1 (ru)
UA (1) UA95274C2 (ru)
WO (1) WO2007080074A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006006588A1 (de) 2006-02-13 2007-08-16 Ratiopharm Gmbh Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung
ES2377239T3 (es) * 2007-04-17 2012-03-23 Ratiopharm Gmbh Composiciones farmacéuticas que comprenden irbesartán
ES2349317T3 (es) 2007-11-28 2010-12-29 Laboratorios Lesvi, S.L. Formulaciones farmacéuticas que contienen irbesartán.
WO2011141783A2 (en) 2010-04-13 2011-11-17 Micro Labs Limited Pharmaceutical composition comprising irbesartan
CN101912390A (zh) * 2010-08-08 2010-12-15 浙江华海药业股份有限公司 含厄贝沙坦的药用组合物
CN103191076B (zh) * 2013-04-27 2016-08-17 吕丕平 一种厄贝沙坦片剂的制备方法
JP6445923B2 (ja) * 2015-04-22 2018-12-26 ダイト株式会社 イルベサルタン含有錠剤の調製方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
NZ237476A (en) 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2780403B3 (fr) 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
US20050176793A1 (en) 2001-12-10 2005-08-11 Reddy Reguri B. Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one
AU2003256609A1 (en) 2002-07-16 2004-02-02 Teva Pharmaceutical Industries Ltd. Novel synthesis of irbesartan
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006013545A1 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Pharmaceutical compositions of irbesartan
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
GB2419592A (en) * 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation

Also Published As

Publication number Publication date
EA200801634A1 (ru) 2008-10-30
EA016579B1 (ru) 2012-06-29
EP1806130B1 (en) 2010-03-31
NO20083183L (no) 2008-09-26
CN101370484A (zh) 2009-02-18
CN101370484B (zh) 2011-06-01
ATE462414T1 (de) 2010-04-15
PT1806130E (pt) 2010-05-11
CA2636663A1 (en) 2007-07-19
EP1981485A1 (en) 2008-10-22
HRP20100216T1 (hr) 2010-05-31
EP1806130A1 (en) 2007-07-11
EP1981485B1 (en) 2014-10-08
SI1806130T1 (sl) 2010-06-30
US20110045097A1 (en) 2011-02-24
DE602006013261D1 (de) 2010-05-12
PL1806130T3 (pl) 2010-08-31
WO2007080074A1 (en) 2007-07-19
ES2340701T3 (es) 2010-06-08

Similar Documents

Publication Publication Date Title
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2007017135A3 (en) Process for the preparation of olmesartan medoxomil
EP2178869A4 (en) INDOLE COMPOUNDS AS INHIBITORS OF CELL NECROSIS
WO2007086078A3 (en) Novel pharmaceutical compositions and process of preparation thereof
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
UA96575C2 (en) Process for the preparation of olmesartan medoxomil
ZA200806778B (en) N-Hydroxyacrylamide compounds
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
MX2009005368A (es) Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina.
ZA201003380B (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and methhod for the preparation thereof
MY144613A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
NO20082140L (no) Fremgangsmate til fremstilling av kandesartancileksetil
TW200716114A (en) Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
WO2007052167A3 (en) Stable composition for a pharmaceutical formulation containing olanzapine
WO2010018593A3 (en) Gastric acid resistant benzimidazole multiple unit tablet composition
MY143949A (en) An orally active thrombin inhibitor
UA91073C2 (en) Process for the preparation of candesartan cilexetil
WO2008117154A3 (en) Stable pharmaceutical compositions, preferably tablets, of hmg-coa reductase inhibitor and process for preparation thereof
WO2006092732A3 (en) Stable solid dosage form of antihypertensive agent